You are here: Industry Insights > Market News > SEC meets to discuss EUA applications from Pfizer, SII and Bharat Biotech

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

SEC meets to discuss EUA applications from Pfizer, SII and Bharat Biotech

expresspharmaDecember 31, 2020

Tag: SEC , SII , Bharat Biotech

Favorites

The Subject Expert Committee (SEC) in the Central Drugs Standard Control Organisation (CDSCO) met on December 30, 2020, in the afternoon to consider the Emergency Use Authorisation (EUA) requests of Pfizer, Serum Institute of India (SII) and Bharat Biotech.

Further time was requested on behalf of Pfizer. The additional data and information presented by SII and Bharat Biotech were perused and analysed by the SEC.

The analysis of the additional data and information is going on. SEC will convene again on January 1, 2021.

Previous:Recipharm, Moderna sign deal for manufacturing, fill-finish of COVID-19 vaccines

Next:Awaiting India’s approval for COVISHIELD: SII

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs

PharmaSourcesJune 05, 2024

New research showes that biotechs can save more than 30% in costs, halve start-up times, and cut risk with CROs that have in-house scientific and regulatory affairs.

SEC meets to discuss EUA applications from Pfizer, SII and Bharat Biotech

Related News

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs

You may like